MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 05-14-2025
OptiNose Book Value 2011-2026 | OPTN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OptiNose
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.6 M | -56.6 M | -21.8 M | 6.79 M | 61.6 M | 119 M | 154 M | -3.84 M | -27.1 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -86.6 M | 16.2 M |
Quarterly Book Value OptiNose
| 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -61.4 M | -40.4 M | -41.1 M | -42.9 M | -99.2 M | -86.6 M | -77.6 M | -69.7 M | -73.8 M | -56.6 M | -73.4 M | -60.8 M | -44.9 M | -21.8 M | -51.5 M | -37.1 M | -16.7 M | 6.79 M | 6.79 M | 6.79 M | 6.79 M | 61.6 M | 61.6 M | 61.6 M | 61.6 M | 119 M | 119 M | 119 M | 119 M | 154 M | 154 M | 154 M | 154 M | 17 M | 17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 154 M | -99.2 M | 12.7 M |
Book Value of other stocks in the Drug manufacturers industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Assertio Holdings
ASRT
|
94 M | $ 19.49 | 1.46 % | $ 125 M |  USA |
 |
Bausch Health Companies
BHC
|
-82 M | $ 5.39 | 0.47 % | $ 1.97 B |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
17 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-651 K | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-17.3 M | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
487 M | $ 1.0 | 0.5 % | $ 108 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
22.5 M | $ 3.16 | -0.47 % | $ 44.4 M | USA |
 |
Cronos Group
CRON
|
1.71 B | $ 2.59 | 2.17 % | $ 1.36 B | Canada |
 |
Avadel Pharmaceuticals plc
AVDL
|
73.8 M | - | - | $ 2.06 B |  France |
 |
Evolus
EOLS
|
-23.1 M | $ 4.13 | 2.48 % | $ 266 M | USA |
 |
Catalent
CTLT
|
3.6 B | - | - | $ 11.5 B | USA |
 |
Agile Therapeutics
AGRX
|
-16.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
46.2 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-24.2 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
52.1 M | $ 35.33 | 0.06 % | $ 1.3 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
234 M | - | -39.89 % | $ 27.7 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Evoke Pharma
EVOK
|
-2.58 M | - | - | $ 36.6 M | USA |
 |
HEXO Corp.
HEXO
|
314 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
OrganiGram Holdings
OGI
|
306 M | $ 1.4 | 1.09 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
385 M | $ 2.3 | 2.67 % | $ 303 M | USA |
 |
Aurora Cannabis
ACB
|
609 M | $ 3.46 | 0.44 % | $ 86.3 M | Canada |
 |
Pacira BioSciences
PCRX
|
778 M | $ 22.41 | -1.28 % | $ 1.04 B | USA |
 |
Relmada Therapeutics
RLMD
|
86.5 M | $ 6.97 | -0.29 % | $ 275 M | USA |
 |
Rockwell Medical
RMTI
|
37 M | $ 0.93 | -3.32 % | $ 33.5 M | USA |
 |
SCYNEXIS
SCYX
|
49.4 M | $ 0.93 | 5.03 % | $ 46.4 M | USA |
 |
Solid Biosciences
SLDB
|
180 M | $ 7.84 | 4.67 % | $ 686 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.41 M | $ 2.32 | -2.11 % | $ 2.88 M | USA |
 |
Tilray
TLRY
|
3.33 B | $ 6.78 | 3.44 % | $ 4.19 B | Canada |
 |
Veru
VERU
|
32.3 M | $ 2.34 | 2.18 % | $ 316 M | USA |
 |
Jupiter Wellness
JUPW
|
35 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
21.1 B | $ 13.39 | -0.41 % | $ 16.1 B | USA |
 |
Lannett Company
LCI
|
-251 M | - | 1.15 % | $ 7.11 M | USA |
 |
Emergent BioSolutions
EBS
|
649 M | $ 8.27 | 0.49 % | $ 423 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
265 M | - | - | $ 193 M | Canada |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
PLx Pharma
PLXP
|
51.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
ProPhase Labs
PRPH
|
63.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-252 M | - | - | $ 1.42 B | USA |
 |
Sundial Growers
SNDL
|
1.1 B | $ 1.36 | -0.37 % | $ 3.37 M | Canada |
 |
Recro Pharma
REPH
|
58.7 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
1.96 M | $ 0.74 | 0.61 % | $ 3.19 M | USA |
 |
Zomedica Corp.
ZOM
|
115 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
46.2 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
218 K | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
22.7 M | $ 0.66 | 5.06 % | $ 2.83 M |  China |
 |
TherapeuticsMD
TXMD
|
26.9 M | $ 2.11 | 5.5 % | $ 24.4 M | USA |